The global fiducial markers market is expected to be valued at US$ 2,010.7 Mn in 2021 and expected to grow at a CAGR of 9.4% over the forecast period by 2028. Increasing funds from both private and public sector for intense R&D activities and increasing awareness about the radiotherapy procedure are the drivers boosting the global market. Deficiency in trained and skilled oncologists and the sluggish adoption of advanced technologies are the factors acting as restrains which hung the growth of global fiducial markers market several technological advancements provides a 3D view of fiducials provide multiple opportunities. This report gives comprehensive outlook on fiducial market across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. This report gives historical, current, and future market sizes on the basis of product, modality, application, end user and region. This report studies global fiducial market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global fiducial markers market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global fiducial markers market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and service providers engaged in global fiducial markers market. Market players have witnessed the strategic collaboration and acquisition to expand product portfolio and strengthen their position in the market to enhance the revenue of the company. In 2019, Stratpharma AG (Switzerland) expanded its agreement with CIVCO (US) to distribute CIVCO’s radiotherapy solutions globally. In 2019, IZI Medical Products (US) acquired the RadioMed division of IBA (Belgium), which manufactures the VISICOIL implantable fiducial markers.